| September 17, 2025 |
Analyst/Investor Meetings
|
| September 08, 2025 |
Investor Meetings for Gland Pharma
|
| August 28, 2025 |
Appointment of Secretarial Auditors
|
| August 28, 2025 |
Reappointment of Essaji
|
| August 26, 2025 |
Gland Pharma receives approval from the USFDA for Vasopressin 5% Dextrose Injection USP (RTU vial)
|
| August 12, 2025 |
Press Release approval of Norepinephrine Q1 FY26
|
| August 12, 2025 |
Press Release approval of Cangrelor Q1 FY26
|
| August 05, 2025 |
Earnings Call Recording Q1 FY26
|
| August 05, 2025 |
Outcome of the Board meeting Q1 FY26
|
| August 01, 2025 |
Clarification to NSE and BSE on US Tariffs
|
| July 31, 2025 |
BRSR FY25
|
| July 31, 2025 |
Notice of AGM FY25
|
| July 11, 2025 |
Gland Pharma receives GMP Compliance Certificate from the Danish Medicines Agency for aseptically prepared Powder for injection, infusion and inhalation
|
| July 11, 2025 |
Certificate under Regulation 74(5) of the SEBI (Depository and Participants Regulations), 2018
|
| July 03, 2025 |
Grant of Stock Options under Gland Pharma Employee Stock Option Scheme 2025
|
| June 27, 2025 |
Intimation regarding trading window closure for quarter ended June 30, 2025
|
| June 24, 2025 |
Receipt of EIR from US FDA for Company’s JNPC Facility, Visakhapatnam
|
| June 04, 2025 |
Update on the ANSM Inspection at Cenexi's Fontenay Manufacturing Facility.
|
| June 04, 2025 |
Gland Pharma Receives Approval for Angiotensin II Acetate Injection.
|
| May 22, 2025 |
Grant of Stock Options (Grant I) under Gland Pharma Employee Stock Option Scheme 2025
|
| May 20, 2025 |
Earnings Call Recording Q4 FY25
|
| May 20, 2025 |
Outcome of the Board Meeting
|
| May 18, 2025 |
Intimation regarding ESOP Compensation
Committee Meeting
|
| April 30, 2025 |
Gland Pharma Receives Approval from USFDA
for Latanoprostene Bunod Ophthalmic Solution
|
| April 24, 2025 |
Intimation regarding change in contact
details of RTA
|
| April 10, 2025 |
Certificate under Regulation 74(5) of the
SEBI (Depository and Participants Regulations), 2018
|
| April 03, 2025 |
Gland Pharma receives approval for
Acetaminophen Injection
|
| March 24, 2025 |
Clarifications on ESOP Scheme 2025.
|
| March 11, 2025 |
Appointment of Mr. Wriddhee Maitra as
Vice-President (Human Resources)
|
| February 26, 2025 |
Outcome of Board Meeting
|
| February 26, 2025 |
ESOP
Allotment
|
| February 25, 2025 |
Conclusion of US FDA Inspection at Company’s
JNPC Facility, Visakhapatnam.
|
| February 03, 2025 |
Earnings Call Recording Q3 FY25
|
| February 03, 2025 |
Integrated Filing Financial Q3 FY25
Final
|
| February 03, 2025 |
Outcome of the Board Meeting.
|
| January 20, 2025 |
Update on US FDA Inspection at Pashamylaram
Facility, Hyderabad
|
| January 16, 2025 |
Update on USFDA Inspection at Dundigal
Facility, Hyderabad.
|
| January 15, 2025 |
Update on Appointment of CEO.
|
| January 13, 2025 |
Certificate under Regulation 74(5) of the
SEBI (Depository and Participants Regulations), 2018.
|
| December 27, 2024 |
Intimation regarding trading window closure
for quarter and nine months ended 31st December
2024
|
| December 26, 2024 |
ANSM Inspection at Cenexi's Fontenay
Manufacturing Facility
|
| December 13, 2024 |
Press Release: Gland Pharma receives
approval for Phytonadione Injectable Emulsion
|
| December 03, 2024 |
Resignation of Mr. Ankit Gupta
|
| December 03, 2024 |
Press Release: Gland Pharma receives
approval for Latanoprost Ophthalmic Solution
|
| November 04, 2024 |
Earnings Call Recording
|
| November 04, 2024 |
Outcome of the Board Meeting
|
| October 18, 2024 |
Appointment of Chief Executive Officer
|
| October 16, 2024 |
Certificate under Regulation 74(5) of the
SEBI (Depository and Participants Regulations), 2018
|
| September 30, 2024 |
Intimation regarding trading window closure
for quarter and half year ended 30th September
2024
|
| September 10, 2024 |
Changes(s) in Directorate
|
| August 30, 2024 |
Change(s) in Directorate
|
| August 26, 2024 |
Intimation to shareholders regarding Notice
of 46th Annual General Meeting
|
| August 12, 2024 |
Earnings call Transcript- Q1FY25
|
| August 12, 2024 |
: Change(s) in Senior Management Personnel
(“SMP”)
|
| August 6, 2024 |
Earnings Call Recording
|
| August 6, 2024 |
Disclosure under Regulation 30 read with
Schedule III Para A Sub Para 20 of the SEBI
(Listing Obligations and Disclosure Requirements)
Regulations, 2015
|
| August 6, 2024 |
Conclusion of US FDA Un-announced Inspection
at Pashamylaram Facility, Hyderabad
|
| August 2, 2024 |
Conclusion of US FDA Un-announced Inspection
at Pashamylaram Facility, Hyderabad
|
| July 25 2024 |
Conclusion of US FDA Surprise Inspection at
Dundigal Facility, Hyderabad
|
| July 23 2024 |
Press Release: Gland Pharma receives
Tentative Approval from the USFDA for Latanoprostene Bunod
Ophthalmic Solution
|
| July 15 2024 |
Certificate
under Regulation 74(5) of the SEBI (Depository and
Participants
Regulations), 2018
|
| June 28 2024 |
Intimation regarding trading window closure
for quarter ended 30th June 2024
|
| June 7 2024 |
Allotment of Equity Shares on exercise of
ESOP
|
| June 7 2024 |
Outcome of the Board Meeting
|
| June 7 2024 |
Press
Release: Srinivas Sadu appointed as Executive Chairman and
CEO of Gland Pharma Limited
|
| May 31 2024 |
Change(s) in Senior Management Personnel
(“SMP”)
|
| May 29 2024 |
Earnings call Transcript- Q4FY24
|
| May 24 2024 |
US FDA
Inspection at JNPC Facility, Visakhapatnam
|
| May 23 2024 |
Outcome of the Board Meeting
|
| May 23 2024 |
Intimation regarding the Earnings Call
Q4FY24 Audio recording link
|
| May 07 2024 |
Press Release: Gland Pharma receives
approval for Edaravone Injection
|
| May 07 2024 |
Press Release: Gland Pharma receives
approval for Plerixafor for Injection
|
| April 29 2024 |
Outcome of the
Board Meeting
|
| April 29 2024 |
Press
Release: Gland Pharma receives approval for Cetrorelix
Acetate for Injection
|
| April 17 2024 |
Certificate
pursuant to Regulation 40(9) of the Securities and Exchange
Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015 for the year ended March 31,
2024.
|
| April 11 2024 |
Clarification regarding increase in volumes-
your e-mail dated April 10, 2024.
|
| April 10 2024 |
Certificate under Regulation 74(5) of the
SEBI (Depository and Participants Regulations), 2018.
|
| April 10 2024 |
Certificate
pursuant to Regulation 7(3) of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015 for the year
ended March 31, 2024.
|
| April 8 2024 |
Press Release:
Gland Pharma receives approval for Eribulin Mesylate
Injection.
|
| March 26 2024 |
Intimation regarding trading window closure
for quarter and financial year ended 31st March 2024.
|
| March 26 2024 |
Change(s) in Senior Management
Personnel.
|
| March 26 2024 |
Allotment of Equity Shares on exercise of
ESOP.
|
| Fabruary 21 2024 |
Intimation regarding the Earnings Transcript
Q3FY24 Audio recording link.
|
| Fabruary 15 2024 |
Intimation regarding the Earnings Call
Q3FY24 Audio recording link.
|
| Fabruary 14 2024 |
Outcome of the Board Meeting.
|
| Fabruary 14 2024 |
Allotment of Equity Shares on exercise of
ESOP.
|
| Fabruary 27 2024 |
Change of President for Cenexi.
|
| January 11 2024 |
Certificate under Regulation 74(5) of the
SEBI (Depository and Participants Regulations), 2018.
|
| December 29 2023 |
Intimation regarding trading window closure
for quarter and nine months ended 31st December 2023.
|
| November 24 2023 |
Receipt of EIR from US FDA for Pashamylaram
Facility.
|
| November 20 2023 |
Outcome of postal ballot-reappointment of
Independent Director.
|
| November 15 2023 |
Press Release-Tentative approval from USFDA
for Angiotensin II for Injection.
|
| November 08 2023 |
Conclusion of US FDA Inspection at VSEZ
Sterile Oncology Facility, Visakhapatnam.
|
| November 06 2023 |
Intimation regarding the Earnings Call
Q2FY24 Audio recording link
|
| November 06 2023 |
Outcome of the Board Meeting
|
| October 17 2023 |
Intimation Reappointment of Mr. CSN Murty
Independent Director of the Company.
|
| October 10 2023 |
Intimation regarding ESOP allotment.
|
| September 29 2023 |
Intimation regarding trading window closure
for quarter and half year ended 30th September 2023.
|
| September 26 2023 |
Conclusion of US FDA Inspection at
Pashamylaram Facility of the Company.
|
| September 19 2023 |
Intimation regarding appointment of
President for Cenexi.
|
| September 04 2023 |
Intimation regarding Change of Senior
Management Personnel.
|
| August 31, 2023 |
Intimation regarding appointment of
Statutory Auditors.
|
| August 28, 2023 |
US FDA
Inspection at Pashamylaram Facility, Hyderabad.
|
| August 25, 2023 |
Addendum to the
Notice of the 45th AGM of the Company.
|
| August 23, 2023 |
Conclusion of US FDA Inspection at Dundigal
Facility, Hyderabad.
|
| August 09, 2023 |
Clarofication to BSE in regard to increase
in volume of shares.
|
| August 09, 2023 |
Business
Responsibility and Sustainability Report for the financial
year ended March 31, 2023.
|
| August 09, 2023 |
Notice of the 45th Annual General Meeting
(AGM) along with copy of Annual Report for the year ended
March 31, 2023
|
| August 08, 2023 |
Intimation regarding the Earnings Call
Q1FY24 Audio recording link.
|
| August 07, 2023 |
Outcome Of Board Meeting_Q1FY2024
|
| July 28, 2023 |
Intimation regarding Earnings Conference
Call - Q1FY24
|
| July 28, 2023 |
Announcement regarding US FDA Inspection at
VSEZ Sterile Onclogy Facility
|
| July 14, 2023 |
Announcement regarding US FDA Inspection at
Dundigal Facility
|
| July 12, 2023 |
Reply to Clarification Sought by BSE
|
| July 10, 2023 |
Reply to Clarification sought by NSE
|
| June 29, 2023 |
Intimation regarding Closure of Trading
Window
|
| June 27, 2023 |
Intimation regarding USFDA Inspection at
Pashamylaram Facility.
|
| May 18, 2023 |
Outcome of the Board Meeting.
|
| May 18, 2023 |
Intimation regarding Audio Recording of
Earnings Conference Call Q4 FY 2022-23.
|
| April 27, 2023 |
Announcement regarding Completion of
Acquisition of Cenexi.
|
| April 20, 2023 |
Clarification to BSE.
|
| April 20, 2023 |
Clarification to NSE.
|
| March 29, 2023 |
Intimation to Stock Exchanges Regarding ESOP
Allotment.
|
| March 29, 2023 |
Intimation to Stock Exchanges Regarding
Appointment of Statutory Auditors.
|
| March 24, 2023 |
Closure of Trading Window.
|
| February 04, 2023 |
Intimation to Stock Exchanges Regarding
Notice of Postal Ballot.
|
| January 27, 2023 |
US FDA Inspection JNPC Facility.
|
| January 23, 2023 |
Link of Earning Call Recording for
Q3FY23
|
| January 23, 2023 |
Outcome of the Board Meeting
|
| January 06, 2023 |
Update on proposed acquisition of Cenexi
|
| January 04, 2023 |
Closure of US FDA Audit- Dundigal
Facility
|
| December 30, 2022 |
Closure of Trading Window
|
| November 29, 2022 |
Clarification to Stock Exchanges.
|
| November 29, 2022 |
Intimation regarding Investor Call Recording
|
| November 29, 2022 |
Investors Call Recording
|
| November 29, 2022 |
Investor Presentation on the Proposed
Acquisition of Cenexi Group
|
| November 29, 2022 |
Disclosure regarding the Proposed
Acquisition of Cenexi Group
|
| November 29, 2022 |
Press Release on the Proposed Acquisition of
Cenexi Group.
|
| November 24, 2022 |
ESOP Allotment.
|
| November 04, 2022 |
Related Party Transactions for the half year
ended 30th September 2022
|
| October 26, 2022 |
Intimation of Earnings Call Recording
Q2FY23
|
| October 26, 2022 |
Outcome of Board Meeting
|
| October 10, 2022 |
Board Meeting Intimation
|
| September 30, 2022 |
Closure of Trading Window
|
| September 15, 2022 |
ESOP Allotment.
|
| September 01, 2022 |
Disclosure regarding Retirement of Directors
by rotation.
|
| August 26, 2022 |
Intimation Regarding Notice for
44thAGM
|
| August 25, 2022 |
Update
on US FDA InspectionthAGM
|
| August 08, 2022 |
Newspaper Advertisement regarding Notice of
the 44thAGM
|
| August 05, 2022 |
Notice of 44thAGM
|
| August 05, 2022 |
Newspaper
Advertisement before dispatch of Notice of AGM
|
| July 22, 2022 |
Advertisement on the Unaudited Financial
Results for the Quarter ended June 30, 2022
|
| July 20, 2022 |
Intimation of Earnings Cal Recording
Q1FY23
|
| July 20, 2022 |
Outcome of the Board Meeting.
|
| July 04, 2022 |
Board Meeting
Intimation.
|
| June 30, 2022 |
Closure of Trading Window.
|
| June 15, 2022 |
ESOP Allotment.
|
| May 31, 2022 |
Related Party Transactions for the half year
ended 31st March 2022.
|
| May 20, 2022 |
Advertisement on the Audited Financial
Results for the Quarter and Financial Year ended March 31,
2022
|
| May 19, 2022 |
Outcome of the Board meeting Q4FY22
|
| May 04, 2022 |
Press Release-Launch of Bortezomib for
Injection through our partner in the US Market
|
| April 29, 2022 |
ESOP
Allotment
|
| April 04, 2022 |
Board Meeting Intimation
|
| March 31, 2022 |
Closure of Trading Window
|
| March 22, 2022 |
Newspaper Advertisement for Postal
Ballot
|
| March 21, 2022 |
Intimation of Postal Ballot Notice
|
| March 16, 2022 |
Newspaper Advertisement for Registration of
e-mail address
|
| March 10, 2022 |
Outcome of the Board Meeting- Appointment
and Resignation of Directors
|
| January 22, 2022 |
Advertisement on the Unaudited Financial
Results for the Quarter and Nine months ended December 31,
2021
|
| January 21, 2022 |
Outcome Of The Board Meeting
|
| December 28, 2021 |
Board Meeting Intimation
|
| December 21, 2021 |
ESOP Allotment
|
| December 08, 2021 |
Press Release-Product tentative
approval-Cangrelor for Injection
|
| October 30, 2021 |
Intimation of Related Party filing delay for
half year ending March 31, 2021
|
| October 23, 2021 |
Advertisement on the Unaudited Financial
Results for the Quarter and Half year ended September 30,
2021
|
| October 22, 2021 |
Outcome of the Board Meeting
|
| October 08, 2021 |
Press Release-
Product Tentative approval for Sugammadex Injection, 200
|
| October 7, 2021 |
ESOP Allotment
|
| September 30, 2021 |
Board Meeting Intimation Advertisement
|
| September 29, 2021 |
Board Meeting
Intimation
|
| August 27, 2021 |
Voting Result and Combined Scrutinizer’s
Report of the 43rd AGM
|
| August 27, 2021 |
43rd AGM Proceedings
|
| August 04, 2021 |
Book Closure Intimation
|
| August 04, 2021 |
Notice of AGM Newspaper advertisement
|
| July 22, 2021 |
Advertisement on the Unaudited Financial
Results for the Quarter ended June 30, 2021
|
| July 21, 2021 |
Intimation of Monitoring agency report
|
| July 21, 2021 |
Outcome of the Board Meeting
|
| July 15, 2021 |
Certificate under regulation 74(5) of SEBI
(DP) Regulations, 2018
|
| June 29, 2021 |
Board Meeting intimation advertisement for
the Quarter ended June 30, 2021
|
| June 28, 2021 |
Board Meeting
intimation for the Quarter ended June 30, 2021
|
| June 19, 2021 |
Related Party Transactions for the half Year
ended March 31, 2021
|
| May 18, 2021 |
Newspaper publication on Q4FY21 Results
|
| May 17, 2021 |
Outcome of the Board Meeting
|
| May 12, 2021 |
Intimation of Monitoring Agency
Report-Q4FY21
|
| May 5, 2021 |
Intimation of ESOP Allotment
|
| April 22, 2021 |
Product Approval
|
| April 8, 2021 |
Disclosure pursuant to SEBI Circular No.
SEBI/HO/DDHS/CIR/P/2018/144
|
| April 5, 2021 |
Intimation of newspaper publication on Board
Meeting
|
| April 3, 2021 |
Intimation of Board Meeting
|
| March 16, 2021 |
Intimation of ESOP Allotment
|
| March 16, 2021 |
Intimation under Regulation 30
|
| December 31, 2020 |
Intimation of
Board Meeting
|
| January 23, 2021 |
Intimation of Newspaper advertisement
pertaining to Unaudited Financial Results of Q3 FY 2021
|
| January 22, 2021 |
Intimation of ESOP Allotment
|
| January 22, 2021 |
Outcome of the Board Meeting
|
| January 22, 2021 |
Intimation of Monitoring Agency
Report-Q3FY21
|
| January 1, 2021 |
Intimation of Board Meeting-
Advertisement
|
